Scientist.com and Novaseek Partner to Offer a Patient-Driven Approach to Sourcing Human Biospecimens5/31/2018
Marketplace users now have online access to EMR data and biosamples from consenting patients SAN DIEGO (PRWEB) MAY 31, 2018 Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced today that it has collaborated with Novaseek Research, Inc., a health IT for life sciences organization, to create a first-of-its-kind process for sourcing human biosamples. Scientist.com users can now access Novaseek’s ever-expanding network of patients that have consented to ongoing access to their electronic medical records (EMR) and related biospecimens. “Novaseek’s unique platform helps marketplace users find biospecimens and data that are not available anywhere else,” stated Kevin Lustig, PhD, CEO and Founder of Scientist.com. “Researchers can now use redacted clinical data from consented donors to conduct searches and make smart biospecimen sourcing decisions.” Using its proprietary CDNR platform, which is embedded in a network of participating hospitals, Novaseek scans live EMR data from thousands of consented patients to find precise matches to research requirements; searchable data includes ICD10 diagnoses, medication lists, lab testing results, narrative reports and more. The platform then finds clinical laboratory specimens that are immediately available from these matching subjects – including blood, serum, urine and all types of fluids. “The Scientist.com marketplace is a great way to expose more researchers to our award-winning human sample sourcing platform,” commented Andrei Soran, CEO of Novaseek Research. “The ability to find fresh specimens in real-time based on highly granular data, such as lab test values or medication histories, is unprecedented. And the data keeps coming – updates to the EMR are visible for each case provided.” About Scientist.com Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo among others. Visit scientist.com to learn more. Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram. Media Contact: Sean Preci Director of Communications +1 858 455-1300 ext. 401 About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit http://www.novaseekresearch.com. Link to article: https://www.prweb.com/releases/2018/06/prweb15526124.htm
Novaseek Research and CoxHealth Launch Partnership to Advance Biomedical and Clinical Research4/17/2018
Expands Access through CDNR Platform to Biospecimens from Additional 6 Hospitals and Medical Centers and 80+ Clinics Across 24 Counties
CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Novaseek Research, Inc., a health IT for life sciences company, today launched its partnership with CoxHealth, a health system nationally accredited by DNV GL-Healthcare. The partnership expands access to biospecimens and associated real world clinical data obtained with patient consent and authorization from six CoxHealth hospitals and medical centers, 80+ CoxHealth clinics across 24 counties to clinical researchers for use in discovery, translational medicine, observational and clinical studies. “Our partnership with CoxHealth, one of the largest hospital systems in Missouri and surrounding states, is now active to help streamline the development path based on a better understanding of real world patients,” said Andrei Soran, founder and chief executive officer, Novaseek Research. “As our network of partners utilizing Novaseek’s Clinical Data Network for Research (CDNR) platform continues to grow, there is increased opportunity for researchers to accelerate and streamline the lengthy and costly research process by more precisely identifying patient populations with highly specific characteristics from very early and throughout the development process.” CDNR is an award-winning, cloud-based platform that transforms the way healthcare organizations and consented patients share biospecimens and clinical data with the research community. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories. CDNR enables complex requests such as, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research and allows more hospitals and patients to participate in supporting biomedical research while generating additional revenue. “Our partnership with Novaseek Research further solidifies CoxHealth’s leadership in adopting information technology solutions to improve patient care, enabling us to provide our patients in urban and rural areas alike the opportunity to participate in research and clinical studies,” said Chris Schulze, director, Clinical Research, CoxHealth. “Our contributions to research via the CDNR platform not only expands our offering to patients, but also strengthens CoxHealth’s position as one of the most widely recognized hospitals in our region.” Novaseek Research is increasing its national exposure through exhibits and participation at events such as the Becker’s Hospital Review Ninth Annual Meeting and the 23rd Annual Executive War College meeting taking place May 1 – 2, in New Orleans. Since launching in 2014, Novaseek has assembled a national network of hospital partners and is enabling its growing research customer base to access real world clinical data and biospecimens in a novel way and to bring medical advances to patients faster. by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange
Most everyone knows that precision medicine promises to transform the healthcare landscape, delivering powerful and personalized treatments for previously intractable diseases. Even so, biotech innovators still face tremendous hurdles in realizing this promise — chief among them, finding access to sufficient numbers of annotated, characterized and consented patient samples. Novaseek Research has developed a unique solution to this dilemma: the Clinical Data Network for Research platform — otherwise known as CDNR. CDNR provides instant access to thousands of ethically-sourced patients’ specimens and associated real-world clinical data in pursuit of advancing the field of personalized medicine. Novaseek obtains biosamples and associated data through its extensive network of physicians, clinical labs, and hospitals. Within this network, Novaseek actively recruits patients to match targeted research needs. Novaseek also maintains a large searchable database of de-identified clinical information representing millions of patients. Through the Novaseek platform, researchers can easily obtain the data they need throughout the product life cycle. For instance, researchers seeking the statistics necessary for in vitro diagnostics submissions can gain access to sufficient numbers of annotated, characterized and consented patient samples and related data. With CDNR, obtaining clinical data and biospecimens is seamlessly integrated into R&D. Learn more about Novaseek Research on their Science Exchange storefront  Science Exchange, the world’s leading enterprise platform for outsourced research and development services and acquisition of human biospecimens, announced today its partnership with Novaseek Research Inc., a health information technology for life sciences company.
Now thousands of researchers using Science Exchange have on-demand access to Novaseek’s Clinical Data Network for Research (CDNR) platform to procure biospecimens, with patient consent and authorization, and associated real-world clinical data in pursuit of accelerating medical innovation. Researchers can utilize the CDNR platform in support of discovery, translational medicine, observational and clinical studies while Science Exchange manages the contracting process and tracks analytics to report performance and process improvement. “Our CDNR platform can help accelerate the long and costly research process by precisely identifying patient populations with highly specific characteristics, starting early in the development process and continuing throughout,” said Andrei Soran, CEO of Novaseek Research. “Our partnership with Science Exchange enables clinical researchers to focus on getting medicines to market faster while Science Exchange provides operational and service support.” “The fastest path to novel platforms like Novaseek’s CDNR via Science Exchange helps our leading biopharma clients to accelerate the drug development process and get important medicines to market quickly,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are committed to including the best scientific providers on our platform, and Novaseek meets our stringent vetting criteria. By leveraging population analytics, they help streamline study design and free scientists to focus on innovation.” About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. About CDNR Novaseek’s award-winning, novel, cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time. The CDNR enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. CDNR enables the fulfillment of complex requests, such as the collection of biospecimens and data before and after specific treatments, without burdening patients with extra blood draws or extensive medical questionnaires. This approach allows more hospitals and patients to participate in supporting biomedical research. About Science Exchange Science Exchange is the world's leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.scienceexchange.com. The new partnership will provide Novaseek’s CDNR platform users with an improved experience while expanding Interface People’s customer-centered health IT products, services and solutions to compound growth plans. LEWISVILLE, Texas – Dec. 12, 2017 – PRLog — Interface People (IPeople), a premiere healthcare integration provider and Novaseek Research, Inc., a health IT for life sciences organization, today announced a partnership to enable easier integration of Novaseek’s Clinical Data Network for Research (CDNR) platform into hospital/clinical IT systems. Through this collaboration, Novaseek’s hospital and lab partners will gain access to on-site installation consultants who will install the CDNR platform without disruption of normal workflow. “Partnering with Novaseek builds on our ongoing commitment to continually improve thequality and efficiency of experience with clients’ data,” said Jenny Blue, CEO and Partner of IPeople. “IPeople is excited to be able to assist organizations with clinical research by helping streamline the integration between the HCIS system and Novaseek’s powerful CDNR solution.” “Our partnership with IPeople makes Novaseek’s CDNR platform even easier and simpler to install by removing the implementation burden from the hospital or lab’s IT personnel, freeing them to focus on day-to-day operations,” said Andrei Soran, chief executive officer, Novaseek Research. “By streamlining this process, Novaseek’s hospital and clinical lab partners are able to begin contributing to research and generating revenue with greater ease and speed than ever before.” About CDNR Novaseek’s award-winning novel platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. Hospitals and clinical laboratories are enabled to participate in clinical research at the community level while generating additional revenue. About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. About IPeople As a premiere healthcare integration provider, IPeople combines innovative solutions with in-depth industry knowledge for smarter, easier access to data. IPeople’s HCIS expertise takes them to the next level of building reliable and efficient bi-directional interfaces that organizations can trust. For the last 15 years, IPeople has earned a solid reputation for providing robust and reliable interface solutions to the healthcare community. The IPeople team is committed to continually improving the quality and efficiency of your experience with your data. For more information, please visit http://www.ipeople.com. Media Contacts:
PharmaVOICE’s thought leaders are tackling 10 trends that are expected to incite change in the year ahead. We will be looking at a variety of disparate topics that range from molecule to market in keeping with our publishing focus and philosophy. Click here to read more.
Partnership Enhances Laboratory Revenue Opportunity, Elevates Role in Clinical Research
CAMBRIDGE, MA, and INDIANAPOLIS, IN, September 26, 2017 – Novaseek Research, Inc., a health IT for life sciences company, and hc1.com, inventor of the world’s leading healthcare relationship management (HRM) platform, today announced a partnership to help hospitals and clinical labs enhance their operations through improved performance and additional revenue streams. The collaboration enables hospitals and clinical labs to contribute to research by maximizing use of clinical information and lab specimens while reducing costs and growing lab revenue. “Together Novaseek Research and hc1.com offer unprecedented value to hospitals and clinical labs that are under increased pressure to meet greater demands while facing reduced reimbursements,” said Andrei Soran, Chief Executive Officer, Novaseek Research. “The technology solutions provided via this partnership offer labs a full range of options for improving financial and operational efficiencies while empowering them to take a bigger role in advancing precision medicine using real world data.” “The hc1.com platform enables labs to improve performance while identifying opportunities to increase profitable growth,” said Brad Bostic, founder and CEO of hc1.com. “Through our alliance with Novaseek, labs can now generate revenue by repurposing remnant clinical specimens, increasing the value of their work to the healthcare community while increasing revenue.” Novaseek’s Clinical Data Network for Research (CDNR) platform is a cloud-based platform that transforms the way healthcare organizations and consented patients share biospecimens and clinical data with the research community. The platform constantly scans for laboratory biospecimens that match researchers’ detailed clinical criteria, automating what was once a manual process of biospecimen selection and chart reviews. The CDNR makes it possible to fulfill complex requests, accelerating research and driving additional revenue for clinical labs as they assume a greater role supporting biomedical research. About hc1.com The hc1® Healthcare Relationship Cloud® enables health systems, diagnostic labs and post acute care organizations to grow profitably and deliver amazing service. hc1 has been adopted across more than 1,000 locations across the globe, including Cleveland Clinic, Alere, Nationwide Children’s Hospital and Sonic Healthcare. The company has received accolades from Gartner Research, was named “Best Healthcare CRM for Diagnostic Laboratories” by Frost & Sullivan, and is the current KLAS Healthcare CRM category leader. To learn more, visit www.hc1.com and follow us on Twitter @hc1_HRM, LinkedIn, and Facebook. About CDNR Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time to support research and biobanking workflows before, during and after a study. CDNR enables researchers to define patient cohorts through population analytics, access consented biospecimens and data, and advance translational medicine, clinical development and observational studies. CDNR’s new and improved solution uses historical data and interactive analytics to meet the overlapping needs of organizations involved in clinical data. About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Linda Muskin for hc1.com lmuskin@teamclarus.com (847) 432-7300 Terri Clevenger for Novaseek Research Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 Company Co-Founder to Lead Technology Strategy and Expansion
CAMBRIDGE, MA, June 15, 2017– Novaseek Research Inc., a health IT for life sciences company, today announced that it has named Bennett Malbon as Chief Technology Officer (CTO) for the company. This is an expansion of Bennett’s current role as Vice President, Technology. As CTO, Bennett will be responsible for driving expansion of Novaseek’s Clinical Data Network for Research (CDNR) platform to meet the evolving needs of biomedical and clinical researchers. “Novaseek is growing rapidly, and there is a strong need for someone with Bennett’s talent and vision to help drive strategy for the growth and expansion of our CDNR platform,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Bennett has a proven track record of developing comprehensive clinical data solutions for critical needs within the healthcare and life sciences industries. We are excited to have Bennett in this new position.” “Novaseek is truly innovative in its approach and in the way it enables healthcare organizations and patients to share clinical data and biospecimens for research and provides access for biomedical and clinical researchers to well-categorized patient cohorts for translational and observations studies. I am thrilled to take it to the next level as our team leverages technology to bring better medicines to patients faster,” said Bennett. Bennett helped found Novaseek Research in 2014, He has more than 20 years of experience in IT and software development. Prior to Novaseek, Bennett was the founding technology architect at Curaspan Health Group, which was acquired by Cardinal Health/NaviHealth in 2016, where he led development and roll-out of a patient transition network electronically connecting 600+ acute care health systems to 8000+ post-acute care providers, payers, and medical transportation services, ultimately handling transitions for approximately 20 percent of acute patients in the U.S. Additionally, Bennett worked with PatientKeeper where he oversaw platform strategy and architecture for physician portal and workflow tools, and with HealthGrid, an ambulatory EMR referral and data exchange network. Novaseek’s CDNR is an award-winning, cloud-based platform that provides turn-key access to real world data, patients and biospecimens from a network of healthcare organizations. The CDNR platform enables analysis and prospective observation of well-categorized patient cohorts across multiple disease areas. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens with detailed clinical data using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories. CDNR makes it possible for Novaseek and its hospital partners to serve complex requests, such as, for example, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research, often cutting out up to 12 months of observational study set up and completion and allows more hospitals and patients to participate in biomedical research. About CDNR Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics, and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 For researchers, well-characterized human samples are valuable commodities. And that’s exactly what Novaseek Research delivers to its customers Novaseek’s CEO Kate Torchilin told Clinical Informatics News last month at a meeting in Boston. “Having the biospecimen is very important here,” she said. “You can only deduce so much from data.” Click to read more.
CAMBRIDGE, MA, May 25, 2017– Novaseek Research Inc., a health IT for life sciences company, today announced that it was awarded the Top 10 Clinical Data Management Solution Provider 2017 award by Pharma Tech Outlook. The award recognizes 10 companies at the forefront of providing clinical data management solutions for the pharmaceutical industry and impacting the marketplace.
“Novaseek Research stands out for its solution, the Clinical Data Network for Research (CDNR) platform, that is at the forefront of tackling challenges and is among the leading companies that are real trailblazers in creating benchmarks to be followed,” said Max Wilson, editorial team, Pharma Tech Outlook. Novaseek Research was selected for the Top 10 Clinical Data Management Solution Provider Award by a panel of experts and members of Pharma Tech Outlook’s editorial board. “We are honored to be recognized as a cutting-edge clinical data management solution provider by Pharma Tech Outlook,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Through our CDNR platform, Novaseek is seeking to leverage the power of real world clinical data to facilitate getting better medicines to patients faster.” CDNR is an award-winning, cloud-based platform that transforms the way healthcare organizations and consented patients share biospecimens and clinical data with the research community. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories. The CDNR makes it possible for Novaseek and its hospital partners to serve complex requests, such as, for example, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research and allows more hospitals and patients to participate in supporting biomedical research. Novaseek was featured in the May 2017 edition of Pharma Tech Outlook. Click here for access to the print article and here for access to the online version. About CDNR Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 Novaseek Research Announces Partnership with CoxHealth to Advance Biomedical and Clinical Research4/13/2017
Partnership with Missouri Health System Further Expands Access to Biospecimens and Dynamic Real World Data for Research
CAMBRIDGE, MA, April 13, 2017 (GLOBE NEWSWIRE) – Novaseek Research Inc, a health IT for life sciences company, today announced it has partnered with CoxHealth, one of the nation’s top 100 integrated health systems, to support and expand biomedical and clinical research activity. Through this collaboration, CoxHealth and Novaseek will utilize Novaseek’s Clinical Data Network for Research (CDNR) platform to procure, with patient consent and authorization, biospecimens and associated real world clinical data in pursuit of accelerating medical innovation. The agreement also expands Novaseek’s national network of healthcare organizations that supports discovery, translational medicine, observational and clinical studies. “Novaseek is excited to partner with CoxHealth, one of the largest hospital systems in Missouri and surrounding states,” said Dr. Kate Torchilin, Chief Executive Officer, Novaseek Research. “Novaseek’s objective is to aid researchers in developing better medicine based on better understanding of patients. We also want to help healthcare organizations like CoxHealth balance research engagement with their core mission of providing patient care, as well as giving an opportunity for patients to participate in research.” CDNR is an award-winning, cloud-based platform that transforms the way healthcare organizations share biospecimens and clinical data with the research community. The platform constantly scans for laboratory biospecimens that match researchers’ detailed clinical criteria, automating what was once a manual process of biospecimen selection and chart reviews. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories. The CDNR makes it possible for Novaseek and its hospital partners to serve complex requests, such as, for example, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research and allows more hospitals and patients to participate in supporting biomedical research. “In 2016, CoxHealth was recognized as a ‘Most Wired’ hospital by Hospitals & Health Networks magazine, based on how hospitals across the country are adopting information technology to improve patient care. This same ‘most wired’ philosophy is why we so are excited to employ CDNR to better serve our patients who are interested in participating in research and clinical studies,” said Chris Schulze, Director, Clinical Research, CoxHealth. “Through our partnership with Novaseek Research, we are able to expand our patients’ range of options and enable them to participate in advancing scientific research. This collaboration strengthens CoxHealth’s position as one of the most widely recognized hospitals in our region.” Since launching in 2014, Novaseek has assembled a national network of hospital partners and is enabling its growing research customer base to access real world clinical data and biospecimens in a novel way and to bring medical advances to patients faster. About CDNR Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics and to access consented biospecimens and data to advance translational medicine, clinical development and observational studies. About CoxHealth A community-based, not-for-profit health system, CoxHealth is headquartered in Springfield, Mo., and is nationally accredited by DNV GL – Healthcare. Established in 1906, the organization serves more than 900,000 people in a 24-county service area in southwest Missouri and northwest Arkansas, offering a comprehensive array of primary and specialty care including five hospitals and more than 80 clinics in 25 communities. The health system includes Cox Medical Center South, Cox Medical Center Branson, Cox North Hospital, Meyer Orthopedic and Rehabilitation Hospital, Cox Monett Hospital, Oxford HealthCare, Home Parenteral Services (home infusion therapy), CoxHealth Foundation, Cox College, Cox HealthPlans and more. About Novaseek Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 We are in an exciting time with many innovative companies that are improving parts of the process all the way from development to clinical care, all aimed toward improving the lives of patients. Click here to read more.
Novaseek Research and Repositive won the inaugural 2015 Pistoia Alliance President’s Start-Up Challenge. We spoke with both companies as well as Pistoia president Steve Arlington about the Pistoia Alliance and the intention of the Challenge. Click here to read more.
According to Deloitte, life-sciences companies are evolving their business models from product development through manufacturing and distribution, to move “beyond the pill” and to engage more fully with providers and patients throughout the product lifecycle and “transform what is possible.” Click to read more.
NEW YORK (GenomeWeb) – With its goal of streamlining the process of collecting patient data, Cambridge, Massachusetts-based start-up Novaseek is tackling one of the more challenging portions of the diagnostics and drug-development processes.
Assembly of suitable patient cohorts is among the more expensive and time-consuming parts of such research, and has proven a significant hurdle for many companies, particularly in the molecular diagnostics space where, even after developing a marker or test, firms have struggled to stay afloat financially while generating the large amounts of clinical data required to prove clinical utility and drive adoption. Novaseek CEO Kate Torchilin suggested that these challenges present an opening for her firm, which offers a cloud-based platform to aid researchers in assembling and tracking clinical study cohorts. She added that her previous experience in the clinical diagnostics space has given her a firsthand look at the issue. Prior to joining Novaseek, Torchilin was vice president and general manager of connected health at Alere. From 2003 to 2008 she was the director of global clinical and toxicology markets at Thermo Fisher Scientific where she helped establish the company's clinical and toxicology mass spec business. "My team was actually launching clinical applications of mass spec into diagnostic labs, so both the discovery and validation of [clinical] assays is something that I spent many years being directly involved in," she said. "The challenge that I repeatedly observed throughout my life in diagnostics and research tools and pharma R&D is that disconnect between scientists and clinical researchers in the lab and their ability to formulate experiments and do the discovery that reflects the clinical significance of the disease in the real world," she noted. "That gap was really very, very obvious, both in my groups and other groups around me trying to develop new biomarkers and then launch them." Novaseek is addressing this problem through its cloud-based Clinical Data Network for Research (CDNR) platform, which allows researchers to define patient cohorts, request specimens, and track, manage, and analyze study data. The company aims to bring together what Torchilin said have traditionally been two separate portions of the patient data collection workflow, providing what she described as an "end-to-end solution." Companies like 12B2 (funded by NIH) or Explorys (part of IBM), help researchers develop specific patient cohorts for clinical trials based on de-identified data gathered from sources around the world, Torchilin said. "On the other hand," she added, "there are specimen vendors like BioIVT, Asterand, and iSpecimen that acquire specimens for research from labs." "[Our] value proposition is the ability to integrate the two... providing real world, data- enriched biospecimens for translational medicine, clinical feasibility, and observational studies," Torchilin said. Biospecimens procured using the company's CDNR platform come with fully-consented patient health data from electronic health records, she noted, adding that researchers are also able to follow patients prospectively and collect specimens and clinical data over the course of a treatment or disease. Additionally, she said, the platform provides researchers with historical data on what types of patients present at what clinical sites and how often, allowing them to better understand the subject pools available to them as they work to build their study cohorts. "As a researcher you are usually in the lab, not in the hospital, so you're sometimes several steps separated from the patient," Torchilin said. "You're trying to identify the group of patients, the sub-population, that will give you the maximum chance to discover the biomarker or to validate the marker, or the new test that you're developing. You really need to understand what kind of patients there are, how you define that cohort, and what kind of specimens — from which kind of patients, actually — you will need to collect." She gave the example of a diabetes researchers looking for early prognostic markers for the disease. "Say you're trying to find patients who may have been diagnosed with diabetes less than a year ago, who haven't started metformin, and maybe have [hemoglobin A1c] below a certain level," she said. "Now, as a researcher in the lab, you're thinking, 'Okay, so I think now to validate my marker, I need 1,000 patients like this. And at this point, a huge inefficiency happens. Being a scientist myself, you really don't quite know, is that a realistic request? How many patients, realistically, can you find out there who are at that stage of the disease, with that level of HA1C, who have never taken metformin before?" Novaseek launched in 2014 and began offering services through the CDNR platform last year. According to Torchilin, it has, to date, worked on more than two dozen projects across a variety of categories including oncology, immunoncology, neurology, and cardiovascular disease, and is currently working with four of the top ten global pharma firms as well as several biotech firms and academic teams. The company works with hospitals who are either currently involved in recruitment for clinical studies or are interested in becoming involved, Torchilin said. Its platform can be integrated with the records of the healthcare systems it works with, which, she said, allows it to search for suitable patients in an automated fashion. "Once we have a request from the researcher, we start immediately to look among the patients that we see coming through hospitals, and we very quickly, in an automated way, can identify matches," she said. "The alternative route would be to go and maybe partner with a doctor or with some type of a principal investigator, who will ask his nurse, or [other staff] to find the patients. But once you start asking hospital personnel to do some manual work, it becomes [time consuming] and often inefficient." Currently, Novaseek operates in roughly a dozen hospitals across the US. The company also negotiates access to hospitals outside this group, for instance in cases where customers want to work with a specific key opinion leader or patient population, Torchilin said. She said it takes around two months for Novaseek to get the CDNR platform up and running in a new clinical site. The company has ten employees and is currently funded by customer revenue and private investment, Torchilin said. She declined to say how much private investment it has taken on to date. Novaseek is pursuing CROs and pharmas to employ its clinical data platform, Clinical Data Network for Research (CDNR), said CEO Kate Torchilin in an interview with this news service at the Biotech Showcase conference in San Francisco.
The Cambridge, Massachusetts-based company currently works with two CROs, which Torchilin declined to name, adding that Novaseek is intent on forming more CRO partnerships. Novaseek also works with four large global pharmas and several biotechs and academic institutions, said Torchilin, noting that the firm hopes to triple its number of relationships with pharmas in the coming year. Novaseek is indication agnostic and could work with pharmas or CROs across a wide range of disease areas, he explained. Torchilin pointed to other comparable collaborations in the space that Novaseek could replicate, including the recent merger of Quintiles (NYSE:Q) and IMS Health to form Quintiles IMS Holdings. The ideal partners for Novaseek would have databases of clinical records that require data analysis or have data limitations that Novaseek's services could complement, Torchilin said. Novaseek's software platform is able to retroactively track types of patients from de-identified historical data in ways that other companies currently cannot, Torchilin said. The CDNR platform allows companies to directly interact with data and have access to real-world patient populations with the ultimate goal of increasing trial efficiency and clinical significance, he explained. Novaseek has several different approaches to payment structures with partners, including subscriptions and licensing models with various parts of its platform, said Torchilin, adding that the company is flexible in terms of revenue models. by Alissa Fleck in San Francisco Biospecimens enriched with deep data insights for population analytics, prospective patient tracking and more
CAMBRIDGE, MA, Jan. 9, 2017– Novaseek Research LLC today announced that its Clinical Data Network for Research (CDNR) platform was recently enhanced to include the capability to dynamically collect biospecimens and clinical data from patients during the course of the disease or treatment, as well as with population analytics features that enable researchers to draw insights into the effect of various co-morbidities or drug classes on the progression of the disease. Novaseek offers researchers turnkey solutions for accessing biospecimens from consented patients with associated, detailed clinical data and dynamic real world data for prospective and longitudinal observational studies. “The evolution of medicine and initiatives such as the Personalized Medicine Initiative, the Cancer Moonshot and the guidance in the 21 st Century Cures Act make the need for real world data more compelling than ever before,” said Dr. Kate Torchilin, CEO of Novaseek. “However, until recently there were no effective tools to obtain and utilize real world data in life sciences R&D. CDNR was built with the specific needs of the researcher in mind to enable dynamic data and biospecimen collection. The data available through CDNR can be combined with prospective access to biospecimens at different stages of disease or treatment to give a complete picture of the patient.” The CDNR platform is cloud-based and does not require any installation. Its massive historical clinical data supports population analytics based on detailed criteria such as demographics, primary diagnosis and co-morbidities, lab test results, medications, and clinical procedures, and can aid in the discovery, development and post-launch stages of R&D. Researchers access the platform via an award-winning, intuitive user interface to define patient cohorts, request biospecimens, query data and track for updates. CDNR supports research across multiple therapeutic areas, including oncology, immuno-oncology, CNS, immunology, neuroscience, cardiovascular/metabolic and more. “We recently reached a milestone of one million patient encounters and are poised to at least triple our impact in 2017. CDNR offers researchers an unprecedented depth of insight through biospecimens and patient-level data, dynamic monitoring of consented patient cohorts and population analytics,” said Bennett Malbon, Vice President, Technology, Novaseek Research. Since its launch, Novaseek has grown its clients base to include three of the world’s top 10 largest pharmaceutical companies, several biotechnology companies as well as researchers in academia. About Novaseek Novaseek Research LLC is a game-changing health IT for life sciences company that transforms how biomedical researchers access clinical data and human biospecimens for real world data and observational studies. Novaseek powers speedy and successful discovery, translational medicine and real world data studies by enabling access to dynamic and longitudinal data and biospecimens via its award-winning Clinical Data Network for Research (CDNR) cloud platform. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 Technological advances in an ever-changing healthcare environment, including the digitization of patient health records, have had a significant impact on the development of new therapies. Since first being used to support a drug’s value, real-world data (RWD) is now being pulled into the R&D process at earlier stages to impact the development of new medicines on a more fundamental level. Click here to read more.
BOSTON, Dec. 13, 2016– Novaseek Research LLC, a health information technology for life sciences company, today announced that Kate Torchilin, PhD, MBA, Chief Executive Officer, will present at the upcoming Digital Medicine Showcase 2017, which takes place concurrently with the JP Morgan 35th Annual Healthcare Conference in San Francisco. Dr. Torchilin’s presentation will take place at 2:15 PM Pacific on Tuesday, January 10, at the Parc 55 San Francisco – Union Square.
In her presentation, Dr. Torchilin will provide an overview of Novaseek’s Clinical Data Network for Research (CDNR) platform and discuss how CDNR enables researchers turnkey access to clinical data and data-enriched, consented human biospecimens for use in real-world data and translational medicine studies in the areas of oncology, immune-oncology, cardiovascular disease, diabetes, neuroscience and more. She also will share how CDNR helps researchers define patient cohorts through population analytics and supports historical and longitudinal tracking and the collection of biospecimens and associated clinical data to stratify patients for studies. About Novaseek Novaseek Research LLC is a game-changing health IT for life sciences company that transforms how biomedical researchers access clinical data and human biospecimens for real-world data and precision medicine studies. Novaseek powers speedy and successful discovery, translational medicine, and real-world data studies by providing easy access to patients, longitudinal patient data and biospecimens via its award-winning Clinical Data Network for Research (CDNR) SaaS platform. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com. Media Contact: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326 |
